Granulocyte colony-stimulating factor treatment during radiotherapy is associated with survival benefit in patients with lung cancer

Abstract

Objectives: Granulocyte colony-stimulating factor, an agent commonly used for neutropenia treatment, plays an important role in cancer treatment. However, the effect of granulocyte colony-stimulating factor treatment on patient’s survival during radiation therapy in lung cancer remains unknown. Materials and Methods: A retrospective study of patients with lung cancer who underwent radiation therapy from 2012 to 2015 at Shandong Provincial Qianfoshan Hospital was performed. Granulocyte colony-stimulating factor was administered when grade 3 or 4 leukopenia and/or neutropenia occurred during radiation therapy, and no prophylactic granulocyte colony-stimulating factor was used in this study. Patients were classified into high and low granulocyte colony-stimulating factor group according the dosage of granulocyte colony-stimulating factor use during radiation therapy. The influence of granulocyte colony-stimulating factor on survival was investigated. In addition, the predict value of granulocyte colony-stimulating factor in concurrent chemoradiotherapy group and radiation therapy alone group was also evaluated, respectively. Results: A total of 231 patients were enrolled, with 56 in the high granulocyte colony-stimulating factor group and 175 in the low granulocyte colony-stimulating factor group. High dose of granulocyte colony-stimulating factor for the entire population group was associated with a favorable overall survival (hazard ratio [95% confidence interval] = 1.798 [1.260-2.568]; P =.001) and a longer progression-free survival (hazard ratio = 1.550 [1.127-2.132]; P =.002). However, compared with a lower granulocyte colony-stimulating factor, a higher granulocyte colony-stimulating factor was associated with significant better overall survival and progression-free survival in radiation therapy group, not in concurrent chemoradiotherapy group. Although there was no statistical significance in concurrent chemoradiotherapy group, the median overall survival and progression-free survival of patients in the higher granulocyte colony-stimulating factor group were longer than those in the lower group. Furthermore, the treatment strategy was also associated with the overall survival, not the progression-free survival. Conclusion: This study suggests that granulocyte colony-stimulating factor treatment during radiation therapy has favorable impact on outcome in patients with lung cancer. Besides, results showed that patients treated with concurrent chemoradiotherapy had better prognosis than those treated with radiation therapy alone.